Beijing, China

Guanhua Du

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 4 EPO patents. Top assignees: Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Chinese Academy of Sciences, Shandong Luye Pharmaceutical Co., Ltd.. Active years: 2013-2018.

USPTO Granted Patents = 5 

% Patents Active = 80.0

 

 

Average Co-Inventor Count = 8.6

ph-index = 1


Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Guanhua Du: Innovator in Pharmaceutical Technology

Introduction

Guanhua Du is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical technology, holding a total of 5 patents. His work focuses on the development of innovative drug formulations and methods.

Latest Patents

Among his latest patents is the development of inclusion complexes of pinocembrin with cyclodextrin or its derivatives. This patent outlines the preparation of these complexes, which can be utilized in drug formulation. Another notable patent involves polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride. This disclosure details methods for preparing these polymorphs and their potential applications.

Career Highlights

Guanhua Du has worked with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., where he has contributed to various projects in pharmaceutical research and development. His expertise in the field has led to advancements in drug formulation techniques.

Collaborations

Some of his notable coworkers include Song Wu and Mei Gao, who have collaborated with him on various projects in the pharmaceutical sector.

Conclusion

Guanhua Du's innovative work in pharmaceutical technology and his numerous patents highlight his significant impact on the industry. His contributions continue to pave the way for advancements in drug development and formulation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…